Medication adherence to secondary prevention for coronary artery disease
Adherencia a la prevención secundaria de la enfermedad coronaria

Emiliano Rossi, Gastón Perman, Hernán Michelangelo, Claudia B Alonzo, Laura Brescacin, Karin S Kopitowski, José L Navarro Estrada
2014 Medicina (Buenos Aires)  
We compared the use of evidence-based secondary prevention drugs for coronary artery disease at hospital discharge and 3 years of follow-up in a group of patients associated to an integrated network of health services. We conducted a retrospective group study that included 125 patients under 80 years of age who were hospitalized for acute coronary syndrome. McNemar's test was used to compare values at baseline and 3 years. The mean age of of participants was 63.7 years (SD ± 10.08) and 65.6%
more » ... % CI 56.6-73.9) of male sex. The average follow-up time was 2.94 years (SD ± 0.25). The use of secondary prevention drugs for coronary heart disease decreased at 3 years of follow-up: anti-platelet 97.6 to 88.0% (p = 0.012), beta-blockers 94.4 to 84.8% (p = 0.021) and statins 83.7 to 91.2% (p = 0.035). Patients medicated with a combination of anti-platelet, beta blockers and statins showed a decrease from 86.4 to 66.3% (p < 0.0001). It is necessary to study the causes for the decreased adherence to long-term cardio-protective drugs.
pmid:24736251 fatcat:jq64nrdm45ftdjo32ssk4mn4m4